Drug Store News - Teva Pharmaceuticals
Supplier News — The Food and Drug Administration has granted final approval to Teva Pharmaceuticals for its application for a generic version of Dey’s drug, DuoNeb.
DuoNeb is a bronchodilator that increases airflow by dilating the bronchi and bronchioles. The generic albuterol sulfate and ipratropium bromide inhalation solution will be available in 3 mg (0.083 percent) and 0.5 mg (0.017 percent).
Related Results
Levalbuterol No More Efficacious Than Racemic Albuterol in Treatment of…Albuterol sulfateAlbuterol advisoryLevalbuterol beat albuterol on hyperactivityNew generic albuterol medication
The branded product had annual sales of approximately $265 million in the United States for the 12 months ended Sept. 30, 2007, based on IMS sales data. The company will begin shipping the product immediately.
COPYRIGHT 2008 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
